Alvotech Q1 Revenue Falls to $105.9M, Provides $650M-$700M 2026 Outlook
ALVO is trading near its 52-week low of $3.03 (5.6% above the low).
Summary
Alvotech reported Q1 2026 revenues of $105.9 million, a decrease from $132.8 million in the prior year, with adjusted EBITDA of $24.4 million. The company attributed the revenue decline to a temporary slowdown in production for facility improvements. Alongside these results, Alvotech issued 2026 revenue guidance of $650-$700 million and adjusted EBITDA of $180-$220 million. Strategically, the company submitted Marketing Authorization Applications to the European Medicines Agency for two biosimilars, commenced a pivotal study for AVT29, and entered a manufacturing agreement with FUJIFILM Biotechnologies. While the Q1 revenue miss is a near-term negative, the explanation of temporary production issues and the positive strategic developments, including new guidance, provide a forward-looking view. Traders will be watching for progress on FDA resubmissions and the resumption of normal production to meet the 2026 outlook.
At the time of this announcement, ALVO was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $3.03 to $11.85. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.